Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Music therapy as an adjunctive treatment for refractory epilepsy
Epilepsy/Clinical Neurophysiology (EEG)
P7 - Poster Session 7 (5:30 PM-6:30 PM)
12-002
To study the efficacy of music therapy as an adjunctive treatment in medically refractory epilepsy. 
Medication refractory epilepsy is seen in as many as 40% of patients with epilepsy. Music therapy, specifically studied using passive exposure to Mozart Piano Sonata K. 448, as an adjunct treatment for patients with drug-resistant epilepsy has sparked interest and research over the years.
We searched PubMed using the search terms: Mozart AND Epilepsy or Seizure which resulted in thirteen articles, including one meta-analysis and one randomized controlled trial which were analyzed and reviewed. 
In the RCT, 73 subjects with either idiopathic or structural epilepsy were studied over a three year period to investigate the ability to reduce or prevent seizure activity through passive nightly exposure to music. A 24% reduction in seizure activity from baseline rate was observed in the treatment group exposed to music therapy (P = 0.024), while a 9.6% increase in seizure rate was noted in the control group. For one year post-music exposure, the treatment group was also found to have a 33% reduction in seizure activity (P = 0.002) compared to a 25% increase in the control group. In the meta-analysis, 84% of patients exposed to Mozart were found to have a decrease in interictal epileptiform activity. There was also found to be a 31% reduction in interictal discharges during music exposure and a 23% reduction that carried over post-exposure; however these results were not found to be statistically significant. 
Music therapy appears to have potential as a non-invasive and inexpensive adjunct therapy for medically refractory epilepsy, but more randomized controlled trials with larger sample sizes are needed before it can be determined whether this therapy has clinical utility. 
Authors/Disclosures
Anna Babaie, DO
PRESENTER 		Dr. Babaie has nothing to disclose.
Shirley Ju, MD No disclosure on file
Sami Bajwa, MD (Kaiser Permanente) No disclosure on file